TREVI THERAPEUTICS INC (TRVI) competitors & alternatives
Health Care · NASDAQ
TREVI THERAPEUTICS INC (TRVI)'s top competitors and alternatives — its most similar public companies — include Merck & Co. (MRK), ASTRAZENECA PLC (AZN), CONTINEUM THERAPEUTICS INC CLASS A (CTNM), TECTONIC THERAPEUTIC INC (TECX), UPSTREAM BIO INC (UPB), DESIGN THERAPEUTICS INC (DSGN), MONOPAR THERAPEUTICS INC (MNPR), REZOLUTE INC (RZLT), ANNEXON INC (ANNX), ATAIBECKLEY INC (ATAI), GENERATE BIOMEDICINES INC (GENB) and TYRA BIOSCIENCES INC (TYRA). These are TREVI THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TRVI competitors & alternatives
-
Merck & Co.MRKHealth Care
Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
$127.47 (as of 2026-07-22) · market cap $315.3B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
CONTINEUM THERAPEUTICS INC CLASS ACTNMHealth Care
A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791…
$14.73 (as of 2026-07-22) · market cap $518M
-
TECTONIC THERAPEUTIC INCTECXHealth Care
A biotechnology company using its proprietary GEODe™ platform to unlock therapeutic protein and antibody treatments for difficult-to-target GPCR-related…
$31.59 (as of 2026-07-22) · market cap $594M
-
UPSTREAM BIO INCUPBHealth Care
Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of…
$6.59 (as of 2026-07-22) · market cap $376M
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
ANNEXON INCANNXHealth Care
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical…
$5.23 (as of 2026-07-22) · market cap $857M
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
Not quite? Describe exactly what you want →
Peers are TREVI THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: TREVI THERAPEUTICS INC (TRVI).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.